Baseline characteristics

Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial · Source last updated 2019-08-19

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms

1. counts

   1. group Id

      BG000

      value

      146

   2. group Id

      BG001

      value

      73

   3. group Id

      BG002

      value

      219

   units

   Participants

groups

1. description

   5 milligram tablets administered orally in an outpatient setting according to the protocol-specified dosing schedule

   id

   BG000

   title

   Ruxolitinib

2. description

   Commercially available therapy, oral or parenteral, per manufacturer's instructions and Investigator discretion. BAT included the option of no treatment.

   id

   BG001

   title

   Best Available Therapy (BAT)

3. description

   Total of all reporting groups

   id

   BG002

   title

   Total

measures

1. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            spread

            9.74

            value

            65.1

         2. group Id

            BG001

            spread

            10.27

            value

            65.2

         3. group Id

            BG002

            spread

            9.89

            value

            65.2

   dispersion Type

   STANDARD_DEVIATION

   param Type

   MEAN

   title

   Age, Continuous

   unit Of Measure

   years

2. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            value

            63

         2. group Id

            BG001

            value

            31

         3. group Id

            BG002

            value

            94

         title

         Female

      2. measurements

         1. group Id

            BG000

            value

            83

         2. group Id

            BG001

            value

            42

         3. group Id

            BG002

            value

            125

         title

         Male

   param Type

   COUNT_OF_PARTICIPANTS

   title

   Sex: Female, Male

   unit Of Measure

   Participants

3. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            value

            77

         2. group Id

            BG001

            value

            39

         3. group Id

            BG002

            value

            116

         title

         Primary Myelofibrosis

      2. measurements

         1. group Id

            BG000

            value

            48

         2. group Id

            BG001

            value

            20

         3. group Id

            BG002

            value

            68

         title

         Post-polycythemia vera-myelofibrosis

      3. measurements

         1. group Id

            BG000

            value

            21

         2. group Id

            BG001

            value

            14

         3. group Id

            BG002

            value

            35

         title

         Post-essential thrombocythemia-myelofibrosis

   description

   Disease characteristics at baseline. Overall, (primary myelofibrosis (PMF), post-polycythemia vera-myelofibrosis(PPV-MF) and post-essential thrombocythemia-myelofibrosis (PET-MF) were diagnose in participants. The frequency of PMF was similar between ruxolitinib and BAT arms. In addition, the frequencies of PPV-MF and PET-MF were also similar between both treatment arms.

   param Type

   COUNT_OF_PARTICIPANTS

   title

   Disease Profile - Type of Myelofibrosis (MF)

   unit Of Measure

   Participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice